JP2012520306A - 免疫調節治療剤 - Google Patents

免疫調節治療剤 Download PDF

Info

Publication number
JP2012520306A
JP2012520306A JP2011554122A JP2011554122A JP2012520306A JP 2012520306 A JP2012520306 A JP 2012520306A JP 2011554122 A JP2011554122 A JP 2011554122A JP 2011554122 A JP2011554122 A JP 2011554122A JP 2012520306 A JP2012520306 A JP 2012520306A
Authority
JP
Japan
Prior art keywords
fibrinopeptide
disease
peptides
patient
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011554122A
Other languages
English (en)
Japanese (ja)
Inventor
メリング，ミツチエル・ジエイ
メリング，ウエイド・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2012520306A publication Critical patent/JP2012520306A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
JP2011554122A 2009-03-09 2010-03-09 免疫調節治療剤 Withdrawn JP2012520306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15852609P 2009-03-09 2009-03-09
US61/158,526 2009-03-09
PCT/US2010/026665 WO2010104854A2 (en) 2009-03-09 2010-03-09 Immunomodulatory therapeutic agents

Publications (1)

Publication Number Publication Date
JP2012520306A true JP2012520306A (ja) 2012-09-06

Family

ID=42729052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554122A Withdrawn JP2012520306A (ja) 2009-03-09 2010-03-09 免疫調節治療剤

Country Status (13)

Country Link
US (1) US20110318375A1 (https=)
EP (1) EP2405935A2 (https=)
JP (1) JP2012520306A (https=)
KR (1) KR20120008029A (https=)
CN (1) CN102439175A (https=)
AU (1) AU2010222851A1 (https=)
BR (1) BRPI1009569A2 (https=)
CA (1) CA2753871A1 (https=)
EC (1) ECSP11011373A (https=)
MX (1) MX2011009475A (https=)
RU (1) RU2011137856A (https=)
SG (1) SG174290A1 (https=)
WO (1) WO2010104854A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018163071A (ja) * 2017-03-27 2018-10-18 京都府公立大学法人 関節リウマチに関するペプチドマーカー

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837358B (zh) 2012-12-14 2019-03-29 希尔氏宠物营养品公司 用于陪伴动物的抗衰老食物
EP3439683A4 (en) * 2016-04-04 2020-07-29 Marpe Holdings, LLC MODULATION OF THE IMMUNE SYSTEM FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS
CN110045130B (zh) * 2019-04-17 2022-03-29 中山大学附属第一医院 一种与IgA肾病相关的多肽的免疫分析检测试剂盒
WO2025017038A2 (en) * 2023-07-17 2025-01-23 Angus Dalgleish Serum-derived peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673561B1 (en) * 1999-06-30 2004-01-06 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
WO2003065997A2 (en) * 2002-02-06 2003-08-14 Vicor Technologies, Inc. Anti-infarction molecules
US20080294261A1 (en) * 2007-05-24 2008-11-27 Kevin Pauza Method for treating herniated discs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018163071A (ja) * 2017-03-27 2018-10-18 京都府公立大学法人 関節リウマチに関するペプチドマーカー

Also Published As

Publication number Publication date
RU2011137856A (ru) 2013-04-20
CA2753871A1 (en) 2010-09-16
KR20120008029A (ko) 2012-01-25
ECSP11011373A (es) 2011-11-30
SG174290A1 (en) 2011-10-28
WO2010104854A3 (en) 2010-11-04
BRPI1009569A2 (https=) 2016-03-22
AU2010222851A1 (en) 2011-09-15
US20110318375A1 (en) 2011-12-29
EP2405935A2 (en) 2012-01-18
CN102439175A (zh) 2012-05-02
MX2011009475A (es) 2011-12-08
WO2010104854A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
US8637034B2 (en) Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
US11103530B2 (en) Methods of improving or accelerating postoperative recovery
HU214905B (hu) Eljárás VIII. faktor izolálására
JP2012520306A (ja) 免疫調節治療剤
CA3151943A1 (en) Blood plasma fractions for use in muscle regeneration
US20240239841A1 (en) Peptide and method for treating pain using the same
CN101062413A (zh) 抗犬细小病毒卵黄抗体生物制剂的制备方法
Czajka et al. Mechanism of Vipera berus venom activity and the principles of antivenom administration in treatment
CN103087194B (zh) 一种抗血循型蛇毒鸡卵黄抗体及其应用
JP6059578B2 (ja) フコイダンを含有する止血促進剤
RU2405560C1 (ru) Средство для защиты клеток мозга
CN1248735C (zh) 心脏毒素的制备方法及用途
CN1128810C (zh) 防治肝病的鲨鱼肝多肽结构及纯化
RU2446821C2 (ru) Лекарственное средство для лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способ лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями
RU2519196C2 (ru) Лекарственное средство для лечения патологического синдрома и способ лечения рассеянного склероза
US20220079999A1 (en) Antivenom compositions and uses thereof
EA010573B1 (ru) Гепатопротекторное средство и способ его получения
CN120966834A (zh) 一种靶向FcRn和FcγRs的双特异性纳米抗体及其制备方法和用途
RU2509573C2 (ru) Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2522499C2 (ru) Лекарственное средство для лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способ лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями
RU2014141792A (ru) Применение для лечения и профилактики атеросклероза белково-пептидного комплекса (далее-БПК), полученного из эмбриональной нервной ткани или из быстрозамороженного эмбрионального мозга сельскохозяйственных копытных животных, влияющего на обратный транспорт холестерина из сосудистой стенки и профиль активации моноцитов у пациентов с выраженным атеросклерозом магистральных сосудов или с предрасположенностью к сердечно-сосудистым заболеваниям и способ профилактики и лечения пациентов с атеросклерозом артериальных сосудов и с заболеваниями, вызванными атеросклерозом магистральных и периферических сосудов головного мозга, сердца, сосудов нижних конечностей и аорты (два варианта)
WO2006080867A1 (fr) Produit de stimulation de la secretion du facteur viii de coagulation sanguine

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130604